What are the ELAINE studies?
The ELAINE studies are investigating oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer expressing an ESR1 mutation.
The ELAINE-1 study, found here and the ELAINE-2 study, found here on ClinicalTrials.gov are active, with enrollment complete.
Each participant had disease progression on previous hormonal treatment with an aromatase inhibitor (AI) in combination with a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6 inhibitor).*
Plans for the ELAINE-3 study are underway.
All product names, trademarks, and registered trademarks are property of their respective owners.
Who is Elaine?
Coming in 2023/2024: The ELAINE-3 study
With the ELAINE-1 and ELAINE-2 studies complete, Sermonix plans to conduct ELAINE-3: a larger, randomized phase 3 study at clinical trial sites across the United States, Europe, Japan, Israel, and Canada.
The ELAINE-3 study design will compare the combination of lasofoxifene and abemaciclib to the combination of fulvestrant and abemaciclib in adults with ER+/HER2- metastatic breast cancer expressing an ESR1 mutation(s).
The ELAINE-3 study is now posted here on ClinicalTrials.gov.
Please check back for more information about the ELAINE-3 study, including clinical site locations.
About the ELAINE-1 study
The ELAINE-1 study investigates an oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic ER+/HER2- breast cancer. Each participant showed progression on previous treatment with an Al in combination with a CDK 4/6 inhibitor* All study participants were expressing an ESR1 mutation.1
Primary Objective:
Evaluated the impact on progression-free survival (PFS) of 5 mg of oral lasofoxifene versus injectable fulvestrant, a treatment commonly used in this population.1
102 total patients
were enrolled in ELAINE-1 at renowned academic institutions including Mayo Clinic, leading cancer centers, and additional trial sites in the United States, Canada, and Israel.1
*AIs include Arimidex (anastrozole), Femara (letrozole), or Aromasin (exemestane). CDK 4/6 inhibitors include Kisqali (ribociclib), Ibrance (palbociclib), and Verzenio (abemaciclib).
All product names, trademarks, and registered trademarks are property of their respective owners.
Estrogen receptor mutations have been found in up to 40% of women who progress on endocrine therapy and may produce resistance to other hormonal treatments. This resistance may negatively impact prognosis.2
The ELAINE-1 study was the first to select all study participants prospectively based on ESR1 mutation status. Identifying these patients was achieved using next-generation sequencing (NGS) testing. NGS testing has demonstrated analytical validity to identify ESR1 mutations on patient plasma.3
Ask your physician about NGS testing for the ESR1 mutation.
About the ELAINE-2 study
Primary Objective:
A second study, ELAINE-2, studied the safety and efficacy of the combination of lasofoxifene and abemaciclib.4
Proudly partnering with Lilly® and Verzenio®
Sermonix Pharmaceuticals and associated logos are trademarks of Sermonix Pharmaceuticals. All other trademarks are property of their respective owners.
References: 1. Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation. ClinicalTrials.gov identifier: NCT03781063. Updated August 26, 2021. Accessed July 20, 2022. https://clinicaltrials.gov/ct2/show/NCT03781063 2. Cogliati V, Capici S, Pepe FF, et al. Life (Basel). 2022;12(3):378. 3. Angus L, Beije N, Jager A, Martens JW, Sleijfer S. Cancer Treat Rev. 2017;52:33-40. 4. Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation. ClinicalTrials.gov identifier: NCT04432454. Updated June 7, 2022. Accessed July 20, 2022. https://clinicaltrials.gov/ct2/show/NCT04432454